Document:

Exhibit
10.34

 

Department
of Defense

U.S.
Army Medical Research and Development Command

Congressionally
Directed Medical Research Programs

Fiscal
Year 2022 Peer Reviewed Medical Research Program

Clinical
Trial Award - with Planning Phase

Peer
Review Summary Statement

 

	CDMRP
    Log Number: PR221824	Project
    Duration: 48 months
	Grants.gov
    ID Number: GRANT13697072	Budget
    Requested: $10,118,267
	Review
    Panel: Clinical Trial - Neurological Disorders - 1	Direct
    Costs: $7,621,478
	Discussion
    Period: 10/03/2022-10/04/2022	Indirect
    Costs: $2,496,789

 

Topic
Area: Friedreich’s Ataxia

 

Title:
A Randomized Phase 2 Placebo-Controlled Trial of Resveratrol as JOTROL as a Treatment for Friedreich’s Ataxia

Principal
Investigator: Marshall Hayward 

Performing
Organization: Jupiter Neurosciences, Inc 

Contracting
Organization: Jupiter Neurosciences, Inc

 

OVERVIEW

 

The
Principal Investigator (PI) of this application proposes to assess the safety and tolerability of a new micellar oral formulation of
resveratrol (JOTROL) that demonstrates high bioavailability of resveratrol and its metabolites without any noted adverse effects (AEs)
in a Friedreich ataxia (FRDA) patient population. The study hypothesis is that higher plasma concentrations achieved with JOTROL will
result in greater improvement/less decline in Friedreich Ataxia Rating Scale (FARS) score at 24 weeks than in those receiving placebo
and with fewer dose-limiting GI side effects than observed in earlier trials of resveratrol. The specific aims are (1) to establish the
safety and tolerability of resveratrol as JOTROL over a 24-week period, (2) to determine the PK/PD in FRDA patients in comparison to
the healthy subjects from the earlier phase 1 trial, and (3) to compare the change in FARS score, as well as several other neurologic,
cardiac, and patient reported outcome measures, markers for oxidative stress, and frataxin levels from baseline to 24 weeks following
treatment with JOTROL versus placebo. A phase 2 randomized, double-blind, placebo-controlled, 2-leg, 52-week crossover cohort trial of
JOTROL (500 mg BID) compared to placebo in FRDA patients (24-week treatment period/4-week washout) will be performed. The projected results
are that the higher plasma concentrations achieved with 500 mg BID JOTROL for 24 weeks will result in improved FARS score at 24 weeks
than those receiving placebo and with fewer or no dose-limiting gastrointestinal side effects, with the goal of enabling a larger phase
3 efficacy trial. A planning phase is requested to secure an IND for FRDA, to identify additional clinical sites, and to validate the
quality of gelatin from a new supplier for the JOTROL gelcaps.

 

Procurement
Sensitive Document

Do
not copy or distribute without CDMRP written permission.

Prepared
by SRA International, Inc., A GDIT Company, a support contractor to CDMRP

 

    	 

    	PR221824
	(Page 2 of 14)

    

 

	 	Average

                                                         Score
	 	Standard

                                                         Deviation

	Overall
                                            Evaluation

    
	1.6

    
	 	0.2
	Rating
    Scale: 1.0 (highest merit) to 5.0 (lowest merit)	(Excellent)	 	 

 

	Criteria

    Rating
    Scale: 10 (highest merit) to 1(lowest merit)
	 	Average

                                                                             Score

	Planning
    Phase	 	8.6
	Clinical
    Impact	 	9.7
	Research
    Strategy and Feasibility	 	8.4
	Intervention	 	8.8
	Regulatory
    Strategy and Transition Plan	 	8.3
	Recruitment,
    Accrual, and Feasibility	 	8.6
	Statistical
    Plan and Data Analysis	 	9.0
	Ethical
    Considerations	 	9.0
	Personnel
    and Communication	 	8.4
	Budget	 	7.4

 

SCORED
CRITERIA

 

Planning
Phase

Average
Score: 8.6

 

Scientist
Reviewer A

 

Strengths:
The plan for obtaining an IND is well described and feasible within the time period allotted. A regulatory sponsor is identified and
has provided a letter of commitment. All study procedures, organizational chart, study personnel description, study management plan,
regulatory oversight, and product development plan are all well described.

 

Weaknesses:
No weaknesses were identified.

 

Scientist
Reviewer B

 

Strengths:
The planning phase is planned well, and the IND application for JOTROL is on the right course. JOTROL already has an open IND for mucopolysaccharidosis
type I (MPSI). The phase 1 PK study of JOTROL in healthy adult volunteers has been done. A pre-IND meeting has been held with FDA. Jupiter
Neurosciences Inc (JUNS) is the sponsor which provided a commitment letter. Study procedures, clinical monitoring plan, study population,
inclusion/exclusion criteria, recruitment, ICF, screening, data collection instruments, organizational chart, study personnel, and study/data
management plans are included. Regulatory strategy is explicitly described and supports the planned product indication. IRB and HRPO
applications are planned with anticipated approvals.

 

Weaknesses:
IND for JOTROL in FRDA has not been filed, although IND filing is well planned. This introduces risk into the planning phase. It is unclear
what will happen if the IND for FRDA is not obtained in the 1-year planning phase. No conceptual or logistic plans for developing the
clinical trial network are described. There are no planning meetings proposed for site investigators and coordinators.

 

Procurement
Sensitive Document

Do
not copy or distribute without CDMRP written permission.

 

    	 

    	PR221824
	(Page 3 of 14)

    

 

Scientist
Reviewer C

 

Strengths:
The applicants seem to have already completed pre-IND meetings with the FDA and seem to have a detailed plan in progress for obtaining
IND status.

 

Weaknesses:
No weaknesses were noted.

 

Clinical
Impact

Average
Score: 9.7

 

Scientist
Reviewer A

 

Strengths:
JOTROL would be the first disease modifying treatment for FRDA. Short term benefits include potential improvement in symptoms associated
with FRDA. Long term benefits include potentially slowing cardiomyopathy progression. JOTROL may have benefits in other more common neurodegenerative
disorders by modulating neurodegeneration and oxidative metabolism, as well as improving speech and hearing. The application is consistent
with the FY22 PRMRP topic area of neurology, specifically Friedreich ataxia.

 

Weaknesses:
No weaknesses were identified.

 

Scientist
Reviewer B

 

Strengths:
Since there is no single FDA approved drug for FRDA, the impact on patients, families, caregivers, support organizations, and medical
professionals would be enormous. Scientifically, the successful trial will impact as a strong proof of principle for the mitochondrial
burden being a key pathogenic mechanism leading to the disease. Trials of promising drugs give a hope to the affected. The anticipated
long-term improvement has a potential paradigm shift in patients’ lives.

 

Weaknesses:
FRDA affects many children who have a long future that can be robbed by the disease. While the proposed population is appropriate considering
the average onset of the disease and disability, and the age of death, the exclusion of children should be justified. Excluding children
precludes impact for an important FRDA population.

 

Scientist
Reviewer C

 

Strengths:
This improved drug has significant potential for the treatment of FRDA. Modest but significant effects have been previously obtained
with low bioavailability formulations of the same active component in FRDA patients, so given the markedly improved resveratrol bioavailability
of the JOTROL formulation, it is anticipated that this will be even more significant at slowing down progression of the disease, while
minimizing the occurrence of adverse events such a GI-related complications. As additional validation, the pathway targeted by this drug
is somewhat targeted by another drug (omaveloxolone) currently being investigated for FRDA, and a recent phase 2 trial (Lynch et al 2020)
has shown significantly improved neurological function while being generally safe and well tolerated. It is unclear at this point if
this drug will be effective and, even if it is, how strong that effect will be. That being said, given the debilitating and progressive
nature of FRDA, the development of a drug even with modest ability to slow down symptom progression and prolong a patient’s life
will have tremendous clinical impact for FRDA patients.

 

Weaknesses:
No weaknesses were noted.

 

Procurement
Sensitive Document

Do
not copy or distribute without CDMRP written permission.

 

    	 

    	PR221824
	(Page 4 of 14)

    

 

Consumer
Reviewer

 

Strengths:
The study to investigate the new formulation of resveratrol identified as JOTROL proposed in this application is a clinical trial to
investigate a therapeutic treatment for patients living with Friedreich ataxia as part of the neuroscience topic area. Today there is
no approved treatment or cure for Friedreich ataxia (FA). The motto of the patient community toward research is to “Slow, Stop,
and Reverse” the effects of this disease. This trial is designed to understand the benefits of reducing oxidative stress on the
cells in the nervous system and if they can have a positive influence on frataxin production which is reduced in patients with FA. If
successful, this treatment has the potential to slow the effects of FA and perhaps reverse some of the effects of the disease if a patient
is able to regain some functions previously lost.

 

Without
therapeutic treatments for FA, disease progression is well understood due to previous natural history studies. Over time, patients lose
the ability to walk and lose abilities that help with basic functions that support everyday living such as self-care, dressing, feeding,
and the ability to speak clearly, and they become more dependent on caregivers for support. Patients often suffer from severe fatigue
which makes it even more difficult to perform tasks that support daily living and eventually develop cardiomyopathy often resulting in
death at an early age. Patients with early onset FA (high number of GAA repeats) will lose these abilities sooner and at a much faster
rate and often succumb to the disease at an age as early as their teens or 20s. A treatment that can slow the progression of FA has the
opportunity to delay the age at which they must transition from being ambulatory to using an assistive device, reduce the levels of fatigue,
and provide prolonged independence is viewed as a meaningful change for the patient community.

 

While
previous studies have shown that high doses of resveratrol can cause gastrointestinal side effects, this particular formulation is designed
to reduce or eliminate those adverse effects. Previous safety and tolerability studies suggest gastrointestinal issues should not be
a concern, and this study is designed to continue to evaluate and monitor the tolerability over a longer time period. If successful,
this would be an outstanding achievement for the patient community to provide the first therapeutic treatment to slow the effects of
FA.

 

Weaknesses:
With no approved treatments for Friedreich ataxia today, it is difficult to evaluate the potential long term effects of any potential
therapy. Friedreich ataxia is a disease where its progress is obvious year after year, but not as obvious from one day to the next. Once
the initial phase 2A study is complete, open label extensions could help to provide additional data and feedback on therapeutic benefit
over a longer time period for the patient.

 

Discussion
Notes

 

Reviewers
agreed that an effective treatment of FRDA, whether it is addressing the underlying cause or symptoms, can have a huge clinical impact
and that the proposed treatment, JOTROL, has potential to be a tolerable, effective treatment for some FRDA symptoms. While the evaluation
of potential impact was overwhelmingly positive, one reviewer noted that despite numerous efforts in many indications currently no form
of resveratrol is approved by FDA for any indication. This raised a concern about the approvability and utility of JOTROL for FRDA.

 

Research
Strategy and Feasibility

Average
Score: 8.4

 

Procurement
Sensitive Document

Do
not copy or distribute without CDMRP written permission.

 

    	 

    	PR221824
	(Page 5 of 14)

    

 

Scientist
Reviewer A

 

The
primary objective of Aim 1 of the phase 2A study will be to characterize the safety and tolerability of JOTROL following oral administration
of 500 mg BID, in FRDA patients. Dosing will be conducted under fasting or near fasted conditions. Aim 2 will evaluate PK/PD to help
finalize dosing for a future phase 3 study. Aim 3 will evaluate efficacy of treatment at baseline, 24 weeks (for Period 1), 28 weeks
(baseline for Period 2), and 52 weeks. The primary outcome will be change in FARS score from baseline to end of treatment during both
periods. Secondary outcomes include change on the Friedreich Ataxia Functional Composite (FAFC), Friedreich Ataxia Impact Scale (FAIS),
audiological assessment, and speech assessment. An echocardiogram and several blood biomarkers will also be obtained. Clinical adverse
events will be assessed at each visit. Other assessments including an EKG, blood tests of liver and kidney function, and CBC will be
performed before and after treatment. The Modified Friedreich’s Ataxia Rating Scale (mFARS) will be administered to evaluate for
efficacy.

 

Strengths:
Scientific rationale for the study is well described and based on ample preliminary evidence from other trials. Study design is appropriate
to directly answer study questions, specific aims, and hypothesis. Inclusion/exclusion criteria are appropriate for the study and are
well described. A thorough plan to collect lab specimens is described. All data collection instruments appear to be appropriate for the
study. A crossover design was chosen to enable comparison of outcomes within a single individual, which will increase the power of the
study compared with a parallel group study as it reduces between group variability. This design will also likely increase recruitment
and retainment. The plan for PK/PD analysis is very detailed and well described. The phase 2A study will determine the necessary safety
and tolerability data and outcome parameters to power a phase 2B trial.

 

Weaknesses:
It is not clear if there is any evidence of ongoing benefit after washout that would make the second group not a true placebo arm. Plasma
half-life is about 9 hours. Almost complete elimination of RSV and metabolites is observed by 72 hours after a single dose. However,
there is no description of elimination after cumulative doses.

 

Scientist
Reviewer B

 

Strengths:
Basic science data of resveratrol’s potential therapeutic effects in the literature are impressive. Previous clinical studies support
safety for use of resveratrol in humans and suggest efficacy in patients with FRDA in an open trial. The hypothesis and specific aims
are straightforward. Inclusion and exclusion criteria are clearly set.

 

Weaknesses:
The lack of clinical trial sites and criteria for such sites introduces strong doubts about feasibility of the proposed phase 2 trial.
The previous clinical trial supposedly showing resveratrol’s therapeutic efficacy was not a blinded study. While 2 different dosages
may be considered controls, the dose was presumably not blinded. Thus, the clinical scientific premise is weakened. Early intervention
generally provides a better outcome than later intervention, and it is not clear why the protocol is not treating children. A lack of
scientific support in preclinical studies of animal model of FRDA is a significant weakness. It is unknown if 4 weeks of washout is sufficiently
long to reverse the clinical therapeutic effects of JOTROL. If the washout period is not long enough, it would affect the statistical
analysis. There is no mention of the lasting therapeutic effects after stopping medication.

 

Procurement
Sensitive Document

Do
not copy or distribute without CDMRP written permission.

 

    	 

    	PR221824
	(Page 6 of 14)

    

 

Scientist
Reviewer C

 

Strengths:
The proposed study is well informed by prior preclinical and clinical studies using low bioavailability formulations of resveratrol,
which is the active component of JOTROL. These prior clinical studies were the foundation for power calculations that informed the sample
size selected. Also, prior PK studies of JOTROL have informed the applicant to pursue appropriate testing with a single dose. Data and
sample collection will be performed by experienced CROs, and the clinical teams will be led by an extremely experienced neurologist.
The primary end points are correctly specified as assessing safety and tolerability of JOTROL and determining potential neurological
benefits. Multiple appropriate secondary outcomes are also proposed, including cardiac and neurologic assessments, as well as quantification
of various blood biomarkers. Inclusion/exclusion criteria seem appropriate.

 

Weaknesses:
No weaknesses were noted.

 

Discussion
Notes

 

A
reviewer was concerned that the mechanism of action of resveratrol/JOTROL is unknown. Broad effects of resveratrol on many physiological
processes have been described, and it is not clear that JOTROL addresses specific FRDA symptoms. Lack of defined mechanism and lack of
preliminary data in FRDA animal models reduced this reviewer’s enthusiasm for studying JOTROL as a treatment for FRDA.

 

Intervention

Average
Score: 8.8

 

Scientist
Reviewer A

 

Resveratrol
(RSV) is a naturally occurring compound found in certain foods. It has systemic anti- inflammatory properties; improves neuronal survival
and function; acts as a free radical scavenger, histone deacetylase inhibitor via SIRT1 activation; and stimulates mitochondrial biogenesis.
It has been shown to increase FXN expression both in vitro and in vivo. In preclinical models, RSV reverses cognitive impairment, decreases
neuronal cell death, and reduces neuroinflammation biomarkers. Open- label, proof of principle study of RSV showed evidence of clinical
benefit in individuals with FRDA treated with 5 g daily over 12 weeks. RSV has been made into a patented compound, JOTROL, with improved
bioavailability, which allows for administration of a lower dose and fewer side effects. This work has been demonstrated in a human PK
study. Several phase 1 and 2 trials of RSV and SRT-501 (micronized form of resveratrol with somewhat improved bioavailability) have been
conducted and have shown resveratrol to be safe. However, its low bioavailability requires high doses, which then leads to adverse GI
side effects. JOTROL is a new micellar oral formulation of resveratrol, which increases blood plasma levels by at least eightfold compared
with nonformulated RSV, which was demonstrated in a phase 1 clinical trial. No significant adverse events were found in this trial. JOTROL
bioavailability is affected by food, so it will be taken under fasting conditions. JOTROL will be administered in 100 mg gelcaps for
a total of 500 mg twice daily.

 

Strengths:
The study is well supported, and JOTROL will be available throughout the study. JOTROL directly addresses the clinical need in FRDA.
Resveratrol appears to be superior to other interventions currently being studied (idebenone, deferiprone). There is ample preclinical
and clinical support to support the safety and stability of JOTROL.

 

Weaknesses:
No weaknesses were identified.

 

Procurement
Sensitive Document

Do
not copy or distribute without CDMRP written permission.

 

    	 

    	PR221824
	(Page 7 of 14)

    

 

Scientist
Reviewer B

 

Strengths:
JOTROL is manufactured within the study team and available throughout the proposed trial. The dosage and duration are appropriately set
based on the preliminary human data and will test whether it is efficacious in patients with FRDA. Current treatments of FRDA are supportive/palliative,
and there are no FDA-approved drugs for this disabling and fatal disease. The applicant has shown that JOTROL oral administration is
safe and well tolerated. Research procedures are clearly delineated from routine clinical treatments. Consistency of dosing is assured.

 

Weaknesses:
The crossover trial design may complicate the analysis if JOTROL has prolonged efficacy on clinical outcomes (4-week washout may not
be long enough). GI adverse events may still occur, and it is not entirely clear how GI adverse events will be handled.

 

Scientist
Reviewer C

 

Strengths:
This intervention, if successful, clearly targets an unmet clinical need. Currently, there are no disease modifying drugs for FRDA, and
based on preclinical and recent clinical trials, this drug has the potential to do exactly that. This drug formulation is innovative
and clearly resulted in significantly improved resveratrol bioavailability, when compared with existing resveratrol formulations. A distinct
drug developer (Reata Pharmaceuticals) has recently completed a phase 2 clinical trial with a different drug (omaveloxolone) but which
also activates Nrf2. A significant improvement was observed in neurologic function, supporting the therapeutic potential of this pathway.

Substantial
evidence from a recent phase 1 clinical trial (included in application) supports the safety and stability of the intervention.

 

Weaknesses:
The team is currently experiencing delays in drug manufacturing since the contracted vendor has changed the gelatin used in the capsules,
so the applicants will need to perform further testing on the new capsules before initiating the study.

 

Regulatory
Strategy and Transition Plan

Average
Score: 8.3

 

Scientist
Reviewer A

 

Strengths:
Jupiter Neurosciences Inc created and developed JOTROL applicable for treatment of a pipeline of orphan drug candidates, including FRDA
and Alzheimer’s disease. Phase 1 study results showed that JOTROL did not exhibit the GI side effects associated with RSV. Previously
published clinical trials have demonstrated clinical benefit of RSV. The plan will be to ask the FDA for an accelerated approval process.
If not, then the team will conduct a phase 3 trial financed through an equity raise. At the conclusion of the trial, JUNS plans to submit
an NDA application.

The
path to commercialization is realistic and feasible.

 

Technical
Resources International will serve as the regulatory agency with the FDA and will provide expert regulatory support to Jupiter. Jupiter
conducted a pre-IND meeting with the FDA in the FRDA indication, concomitantly with the pre-IND meeting in MPS I. An IND is open in the
MPS I indication, which will be cross referenced for the study. Jupiter developed and submitted an orphan drug designation request for
the use of resveratrol in FRDA, and Jupiter secured an orphan drug designation (ODD) for resveratrol in the FRDA indication. Compliance,
liability, and quality assurance procedures are well described. The data safety and monitoring plan is well described. Jupiter plans
to share study results as broadly as possible while maintaining all patient protection/confidentiality/privacy considerations.

 

Weaknesses:
No weaknesses were identified.

 

Procurement
Sensitive Document

Do
not copy or distribute without CDMRP written permission.

 

    	 

    	PR221824
	(Page 8 of 14)

    

 

Scientist
Reviewer B

 

Strengths:
The regulatory strategy and development plan for the product indication is straightforward, given the drug is efficacious in treatment
of FRDA. Acquisition plans for IND are in place. TRI and JUNS coordinate to address GMP, GLP, and GCP compliance issues. JUNS has a team
for commercialization of JOTROL. JOTROL has been extensively characterized for the PK, PD, toxicity profile. Commercialization of JOTROL
would not have major pharmacological hurdles once the therapeutic efficacy could prevail. Proposed collaborations and other resources
are achievable and evidenced in support letters. The schedule and milestones for the next level of development toward approval by the
FDA are described. The risk analysis is realistic. Intellectual property is addressed with granted US Patent 10,780,056.

 

Weaknesses:
This application includes no specific funding sources or industry partnership to support further development or commercialization of
JOTROL. The schedule and milestones for bringing the intervention to the FDA’s new drug approval are described but not strongly
supported by existing contracts, partnership, or financial arrangements.

 

Scientist
Reviewer C

 

Strengths:
The applicants appear to be familiar with FDA and other regulatory requirements. The transition plan has a good level of detail regarding
future milestones, market analysis, and risk analysis.

 

Weaknesses:
The application states, “Rare disease indications are feasible for JUNS to commercialize by itself,” but it is not clear
what specific funds and resources are available or anticipated toward commercialization for the FRDA indication.

 

Technology
Transfer Specialist Reviewer

 

Strengths:
The regulatory and transition plans have many strengths, are quite thorough, and are bolstered by more details in the rest of the proposal.
Federal regulatory status is described, and acquiring an investigational new drug (IND) is thoroughly discussed. Based on a new similar
open IND they obtained for a different indication, there should be little problem with the currently proposed path based on preliminary
discussions (which included the other IND) with the Food and Drug Administration (FDA). An orphan drug designation was obtained for the
parent compound. Institutional support, including regulatory, by Juniper is strong, and its collaborators, consultants, contract research
organizations, etc, also have a lot of experience in manufacturing, clinical trials, and regulatory compliance. A letter of support is
attached. The plans are achievable as described, and the same is true for progressing to phase 3 and further into the transition phase
if things go well. The current funding strategy is described, and next level funding through the company and potential agencies or partners
is mentioned. Results of the study and other information will be appropriately distributed. Schedules and milestones are detailed in
the proposal. A risk analysis details potential cost issues, manufacturing issues, and sustainability. Intellectual property ownership
is discussed and is also detailed in other parts of the application. Jupiter has exclusive rights to the product and methods of use and
to issued global patents encompassing those rights.

 

Weaknesses:
There are several minor weaknesses, but they are not a major concern. Although phase 3 is mentioned several places in the proposal and
in the plans for the transition phase, there is no discussion of filing a new drug application (NDA), and the only time that NDA is listed
is in the short Milestone section of the Transition Plan as occurring in 2026; however, it is not shown in the detailed schedule or statement
of work in the proposal. Future funding possibilities are described, but not much detail is provided for all available sources and the
plan says if an FDA accelerated approval is not granted, they “will most likely finance this through an equity raise unless non-dilutive
funding is imminently available.” The transition milestone plan concentrates on the proposal not the transition after the proposed
phase 2 trial, but some discussion is provided elsewhere about a phase 3 and other work after phase 2. The risk analysis does not discuss
any scheduling risks for the proposal work or for transition after phase 2; however, scheduling is detailed in several places.

 

Procurement
Sensitive Document

Do
not copy or distribute without CDMRP written permission.

 

    	 

    	PR221824
	(Page 9 of 14)

    

 

Recruitment,
Accrual, and Feasibility

Average
Score: 8.6

 

Scientist
Reviewer A

 

Patients
(100) ages 18 years and older with FRDA will be recruited over a period of 10 months. The patients will participate in 24 weeks of each
treatment (placebo and active intervention) along with a 4- week washout period totaling 52 weeks. Patients will be recruited through
partnership with the Friedrich’s Ataxia Research Alliance who have provided a letter of support, along with the FRDA database and
individuals known to the site investigators. The trial will be conducted at 5 to 8 sites in the USA. Inclusion criteria include (1) 18
years of age or older, (2) genetically confirmed diagnosis of FRDA with homozygosity for GAA triplet expansion in intron 1 of the FXN
gene, (3) mild disease (FARS score of 100 or less), (4) adequate organ function, and (5) written informed consent provided. Exclusion
criteria include (1) nonelective hospitalization within the past 60 days that could be of concern in the investigator’s judgment;
(2) women who are pregnant or lactating or men and women of childbearing potential who are unwilling to use contraception during the
study; (3) FRDA due to compound heterozygosity for an expanded GAA repeat and a point mutation/deletion in the FXN gene; (4) current
or recent (in last 12 months) arrhythmias, cardiac insufficiency, reduced LV ejection fraction (< 50%) in the last 6 months; (5) medical
illness that in the judgment of the investigator would jeopardize the safe completion of the study; (6) evidence of end organ dysfunction
through failure to meet one or more parameters in inclusion criteria; (7) prior invasive cancer (excluding localized basal cell or squamous
cell skin cancer): (8) gastrointestinal disorders that would limit absorption of the investigational product; (9) the use of an investigational
product or intervention other than a noninterventional registry study (including vaccine studies) within 30 days or 10 half-lives prior
to screening or expected during the study; (10) the current use or use within 30 days prior to study of cytochrome P450 inducers/inhibitors,
vitamin E, idebenone, or OTC RSV; (11) participation in another investigational drug or device study within 90 days prior to study enrollment;
and (12) known hypersensitivity to RSV.

 

Strengths:
Having patients as their own controls will likely increase recruitment as everyone gets access to the intervention. Both male and female
subjects will be enrolled. The team aims to recruit a minimum of 20% of historically underrepresented groups. Efforts to recruit and
retain minority groups are well planned. Patients will not know which group they have been assigned to, as well as investigators and
study staff. The team will provide maximal reimbursement possible per visit for participation and provide transportation to and from
study sites to help reduce the burden of participation in the study. The application addresses potential delays in recruitment.

 

Weaknesses:
Other sites have not been chosen yet, which may affect completion of the study.

 

Procurement
Sensitive Document

Do
not copy or distribute without CDMRP written permission.

 

    	 

    	PR221824
	(Page 10 of 14)

    

 

Scientist
Reviewer B

 

Strengths:
The human subject participation in the proposed phase 2 trial is strengthened by the support from the FARA and use of FACOMS and FAGPR.
Plans for the recruitment, informed consent, screening, and retention processes for human subjects are prepared. The burden to study
patients is acceptable. The proposed distribution of the sex/gender, race, and ethnicity of the enrollment patient population is reasonable.

 

Weaknesses:
Sites where study patients will be enrolled have not been determined. Consequently, the qualifications for these sites are unknown. The
quality of sites and site PI are critical elements for successful phase 2 trials. The application does not consider delays in recruitment
is a realistic possibility. However, many studies suffered from unpredicted occurrence, such as the COVID-19 pandemic. There should be
descriptions of basic principles for strategies to cope with such unforeseeable problems. Patients under 18 years of age are not included
in the study. This will exclude pediatric patients who may have even greater needs for therapeutic interventions. At least this age range
should be justified.

 

Scientist
Reviewer C

 

Strengths:
The applicants have established a relationship with FARA which is the primary patient organization for FRDA in the US. A letter of support
confirming that FARA will assist the applicants with enrollment is attached. A recent study aimed at testing a drug with similar mechanism
in FRDA was recently completed (Lynch et al 2020). The study had a similar study design (similar duration, ~1yr) and they were able to
recruit a total of 103 FRDA patients, which is comparable to the hereby proposed 100 FRDA patients. The proposed clinical trial should
have minimal impact on the daily lives of the individual human subjects participating in the study. They will only have a total of 10
visits, and the drug should be taken once daily with fasting (5 x 100 mg capsules).

 

Weaknesses:
The study mentioned above (Lynch et al 2020) was run at 11 clinical sites across the US, Europe, and Australia, so it is unclear if their
proposed design with only 5 to 8 sites in the US will allow for the proposed enrollment goal. Additionally, the applicants state that
they “will recruit a minimum of 20% of historically underrepresented groups to the study.” The similar study mentioned above
(Lynch et al 2020) included only 3 non-white participants in a total of 103 FRDA patients enrolled (< 3%). It is unclear how the applicants
will achieve the proposed target.

 

Statistical
Plan and Data Analysis

Average
Score: 9.0

 

Scientist
Reviewer A

 

Strengths:
Sample size is based on feasibility. A power analysis demonstrated that a sample size of 100 would allow an effect size of 1.84 points
on the FARS to be detected with 80% power.

 

Safety
analysis will be based on the full intent-to-treat population. All analyses described are suitable for the planned study.

 

Weaknesses:
No weaknesses were identified.

 

Scientist
Reviewer B

 

Strengths:
Overall, proposed statistical analyses are sound, including the sample size and power. Parametric and nonparametric data analysis plans
are straightforward.

 

Weaknesses:
Subpopulation analysis is not explicitly proposed, and such plans (such as gender, race, or ethnicity-based response) are deferred to
future studies.

 

Scientist
Reviewer C

 

Strengths:
The applicants have contracted CROs for bioanalytical matters. They are also collaborating with academics with advanced expertise in
statistical analysis. The applicants have used data from prior natural history studies to perform informed power calculations in order
to decide on necessary sample size.

 

Weaknesses:
No weaknesses were noted.

 

Procurement
                                            Sensitive Document

Do
not copy or distribute without CDMRP written permission.

 

    	 

    	PR221824
	(Page 11 of 14)

    

 

Biostatistician
Reviewer

 

Strengths:
The statistical considerations of the proposal are excellent. Specifically, they include a detailed and adequate description of statistical
plans, such as pages 29 to 31; appropriate statistical methods, such as mixed effect model for longitudinal data; and sufficient considerations
of statistical power and solid validation of sample size, especially at page 25.

 

Weaknesses:
No major weaknesses were noted, although the proposed paired t test should have involved regression to address the confounding
demographic factors.

 

Ethical
Considerations

Average
Score: 9.0

 

Scientist
Reviewer A

 

Strengths:
The study will be conducted in accordance with GCP. Informed consent procedures are well described, and participants are allowed to withdraw
from the study at any time. The participant population stands to directly benefit from knowledge gained from the study. Procedures are
consistent with sound research design and pose minimal risk to the participants. Privacy and confidentiality are appropriately considered.

 

Weaknesses:
No weaknesses were identified.

 

Scientist
Reviewer B

 

Strengths:
Patients with FRDA and the FRDA community will benefit from the knowledge gained by this study. Resveratrol has been on their map as
a promising drug. Risk to human subjects and safety monitoring/reporting is acceptable. Lab tests for adverse events (AE and SAE), clinical
outcome assessment measures, and mitochondrial biomarkers have been effectively used in past FRDA studies.

The
consenting procedure is adequate.

 

Weaknesses:
Whether international sites will be considered is not described. Privacy and confidentiality issues are addressed very superficially.
The terms HIPAA or GINA appear not even once in the application. Local recruitment capability is a major factor in securing the sufficient
number of qualified study subject population.

 

Scientist
Reviewer C

 

Strengths:
The population selected to participate in the trial stands to directly benefit from the knowledge gained. Given the study design proposed,
which involves a crossover step halfway through the study, all patients participating in the trial will receive the drug at some point,
during either the first or the last half of the study. This ensures that no patients would receive just placebo throughout the entire
trial. All sites appear to be planned at centers in the US. The study is informed by a prior phase 1 trial where various doses were determined
to be safe. The dose proposed (500 mg) is actually lower than the highest dose tested in the phase 1 study (700 mg), therefore minimizing
the risk to patients.

 

Weaknesses:
No weaknesses were noted.

 

Procurement
Sensitive Document

Do
not copy or distribute without CDMRP written permission.

 

    	 

    	PR221824
	(Page 12 of 14)

    

 

Personnel
and Communication

Average
Score: 8.4

 

Scientist
Reviewer A

 

The
PI, Marshall Hayward, obtained a PhD in biochemistry and molecular biology from the University of Illinois, Urbana, Illinois in 1982.
Currently Dr Hayward is the chief scientific officer of Jupiter Neurosciences LLC.

 

The
Coinvestigator George Wilmot obtained an MD/PhD in medicine/neuroscience from the University of Michigan in 1993. Currently Dr Wilmot
is an associate professor, Department of Neurology, Emory University School of Medicine and director, Emory Ataxia Clinic, Emory University
School of Medicine.

 

The
Coinvestigator Christopher Kemper obtained a PhD in pharmacology from the University of Louisville Medical Center, Louisville, Kentucky,
in 1983. Currently, Dr Kemper is CEO and principal at Pharma Navigators, LLC, Lawrenceville, New Jersey.

 

The
Coinvestigator Shaun Brothers obtained a PhD in physiology and pharmacology from Oregon Health & Science University, Portland, Oregon
in 2003. Currently, Dr Brothers is an associate professor (tenured), psychiatry and behavioral sciences, University of Miami and director,
Sylvester Cancer Center Molecular Therapeutics Shared Resource, University of Miami.

 

Strengths:
The PI has an extensive background in drug discovery, delivery, and clinical development. The PI recently completed the phase 1 trial
for JOTROL. Dr Wilmot is an expert FRDA clinical specialist and will be responsible for clinical study conduct of the trial. Chris Kemper,
PhD, is leading the population PK aspects of the study. Shaun Brothers, PhD, is an expert in translation medication development and a
key advisor to the study team.

 

Weaknesses:
No weaknesses were identified.

 

Scientist
Reviewer B

 

Strengths:
Composition and qualification of the study headquarters team are appropriate. Dr Wilmot is a well-respected, well-informed expert of
Friedreich ataxia, and Dr Hayward has been working on formulation and pharmacokinetics of JOTROL.

 

Weaknesses:
Selection, communication, and execution processes with study sites are not described. No structures or mechanisms for communications
and data transfer between clinical study sites (ie, site PIs and site clinical research coordinators) and Dr Hayward and his team are
described. No standardization and training of PIs, subinvestigators, and clinical research coordinators at clinical trial sites are adequately
described.

 

Scientist
Reviewer C

 

Strengths:
The applicant has assembled a team of collaborators with diverse and complementary expertise, including FRDA clinical specialist and
clinical study design, drug delivery and clinical development, statistics, drug metabolism, and pharmacokinetics. The applicant also
contracted multiple CROs with expertise in running clinical trials.

 

Weaknesses:
No weaknesses were noted.

 

Procurement
Sensitive Document

Do
not copy or distribute without CDMRP written permission.

 

    	 

    	PR221824
	(Page 13 of 14)

    

 

Discussion
Notes

 

Reviewers
did not agree in their evaluation of the study personnel. Some reviewers thought the leadership team is strong and appropriate. The team
gave these reviewers confidence that the study could be successfully conducted. Others felt that uncertainty about the Coinvestigators
at the future clinical sites and the lack of a robust communication plan do not bode well for success of the study.

 

Budget

Average
Score: 7.4

 

Scientist
Reviewer A

 

Strengths:
The budget appears to be appropriate for the study. Weaknesses: No weaknesses were identified.

 

Scientist
Reviewer B

 

Strengths:
Overall costs are reasonable and adequate for a phase 2 trial. The budget for the planning phase is appropriate and < $500,000.

 

Weaknesses:
No detailed budget or budget justification for the subawards (clinical study sites) is included.

 

Scientist
Reviewer C

 

Strengths:
The budget requested for the planning phase and for the clinical trial seems appropriate.

 

Weaknesses:
As clinical sites are not yet identified the budget for the clinical trial is provided in a generic fashion and may or may not reflect
actual cost.

 

UNSCORED
CRITERIA

 

Environment

 

Scientist
Reviewer A

 

The
environment appears appropriate to conduct the study. Jupiter Neurosciences (JUNS) is the sponsor and has provided a letter of commitment.
The CRO is Peachtree Solutions who will hold the central IRB. Technical Resources Intl is the regulatory coordinator side. Catalent is
the trial materials site. Syneos Health will perform all pharmacokinetic analyses.

 

Scientist
Reviewer B

 

The
scientific environment is good and appropriate. Ongoing collaborations are excellent, including accessibility of resources in participating
centers. Institutional commitments for the scientific environment are strong. No clinical sites are selected, and the patient-centric
clinical research environment has not been developed or planned.

 

Procurement
Sensitive Document

Do
not copy or distribute without CDMRP written permission.

 

    	 

    	PR221824
	(Page 14 of 14)

    

 

Scientist
Reviewer C

 

The
drug manufacturing and the majority of the organizational and analytical work will be carried out by different CROs, who seem to have
already been involved in preliminary studies of this drug. Letters of support confirming commitment were provided by all collaborators.
The only aspect of concern is that the clinical sites have yet to be identified, and so far only the clinical lead has been identified
(Dr Wilmot).

 

However,
the applicant proposes to complete the identification of 5 to 8 additional clinical sites during the planning phase.

 

Application
Presentation

 

Scientist
Reviewer A

 

Overall
presentation was decently organized. However, there were a few incomplete edits and unfinished sentences.

 

Scientist
Reviewer B

 

Writing,
clarity, and presentation of data are good.

 

Scientist
Reviewer C

 

The
proposal is mostly written in a clear and accessible manner. There is appropriate use of citations and references. There are some, but
few, typos and other errors, likely due to copy-paste errors from previous studies, eg, “total RSV dose: 1000 mg per day”
and “if the negative effects are not serious and only occur in the high-dose group, an option may be to switch the subject(s) to
the low-dose group,” which are statements inconsistent with the proposed single dose of 500 mg. Another negative aspect is that
many sections were repeated multiple times throughout the proposal, including very similar statements and the same tables and same figures
repeated 2x, which made the review tiring and time consuming.

 

Procurement
Sensitive Document

Do
not copy or distribute without CDMRP written permission.Exhibit 10.1

     

    MINUTES OF SETTLEMENT

    

    

    BETWEEN:

    

    

    DOMENIC SERAFINO

    

    

    and

    

    

    VENUS CONCEPT CANADA CORP.

    

    

    (each a “Party” and together, the “Parties”)

     

    WHEREAS the employment of Domenic Serafino (“Mr. Serafino”) was terminated by Venus Concept Canada Corp. (“Venus” or the “Company”) on or about October 2, 2022 (the “Termination Date”);

     

    AND WHEREAS Mr. Serafino alleged that he was
        wrongfully dismissed from his employment with Venus (the “Claim”);

     

    AND WHEREAS Venus has paid Mr. Serafino all
        outstanding salary, and has continued Mr. Serafino’s base salary and car allowance from the Termination Date;

     

    AND WHEREAS the Parties have agreed to settle all
        matters arising from Mr. Serafino’s employment with Venus and the termination of his employment on the following terms and conditions:

     

    	

          	1.	
            For the purposes of the agreement set out herein, Venus shall include any and all predecessor, successor, affiliated, subsidiary, associated or related companies of Venus, and any and all officers,
              directors, employees, servants, agents, members of the Board of Directors and their successors and assigns as defined herein.

          

     

    	

          	2.	
            Venus will pay Mr. Serafino USD$363,000 in respect of 2021 bonus on or before December 31, 2022.

          

    

    

    	

          	3.	
            Venus will provide Mr. Serafino with outstanding vacation pay for fifteen (15) accrued but unused vacation days on or before December 31, 2022, to be calculated on the basis of gross wages from the
              previous vacation entitlement year in accordance with the Ontario Employment Standards Act, 2000 (the “ESA”).

          

    

    

    	

          	4.	
            Venus will pay Mr. Serafino a combined maximum total of USD $700,000 by October 15, 2023 (the “Pay Period”), representing 15
              months of his regular base salary as at the Termination Date (the “Payment”). The Payment shall be made on the following terms:

          

    

    

    	

          	a.	
            Venus will continue Mr. Serafino’s base salary until March 31, 2023;

          

    

    

    	

          	b.	
            Thereafter, Venus will pay Mr. Serafino the following lump sum payments:

          

    

    

    	

          	i.	
            25% of the remainder of the Payment (having deducted all salary continuance received), on or before April 15, 2023;

          

    

    

    	

          	ii.	
            25% of the remainder of the Payment (having deducted all salary continuance received and the first lump sum payment) on or before June 15, 2023;

          

     

    

    
      Page 1 of 5

      
        

    

    	

          	iii.	
            25% of the remainder of the Payment (having deducted all salary continuance received and the first and second lump sump payments) on or before August 15, 2023; and

          

     

    	

          	iv.	
            25% of the remainder of the Payment (having deducted all salary continuance received and the first, second and third lump sum payments) on or before October 15, 2023.

          

    

    

    Mr. Serafino has a duty to seek alternate comparable employment during the Pay Period, and advise Venus if he finds, or
      becomes self-employed in alternate comparable employment. In the event that Mr. Serafino finds alternate comparable employment or becomes self-employed in comparable employment during the Pay Period, the salary continuance and/or lump sum payments
      will automatically cease and Venus will pay to Mr. Serafino, in a lump sum, fifty per-cent (50%) of the remaining amount of the Payment. In no event will Mr. Serafino receive less than his entitlements under the ESA.

    

    

    All payments will be less deductions required by law, and paid in accordance with Venus’ payroll practices (subject to the
      other terms of this provision).

    

    

    	

          	5.	
            Mr. Serafino’s granted and unvested options, including Restricted Stock Units granted in March 2022, will continue to vest in the regular course per the vesting schedule of the respective grant. Once
              the final tranche of options vests, Mr. Serafino will have thirty (30) days to exercise any remaining unexercised options he may have. As Mr. Serafino last tranche of options is scheduled to vest on March 25, 2026, he will have until April
              24, 2026 to exercise any remaining unexercised options.

          

     

    	

          	6.	
            In the event of a Change of Control, it is agreed that any remaining unpaid portion of the Payment at paragraph 4 will immediately become payable, and all unvested options at paragraph 5 will
              immediately vest and become exercisable for ninety (90) days after Mr. Serafino is notified or becomes aware of the Change of Control. For the purposes of this paragraph, “Change
                of Control” is defined as a completed sale of 75% or more of Venus’ assets.

          

     

    	

          	7.	
            Venus will continue to make its regular contributions to Mr. Serafino’s group health and dental benefit coverage, and provide him with access to his health care spending account until the earlier of
              January 2, 2024, or the date on which he becomes eligible for comparable benefits through alternate comparable employment or becomes self-employed in comparable employment, at which time all benefits will cease. All other benefits have ceased
              or will cease immediately.

          

     

    	

          	8.	
            Venue will contribute $5,000 in respect of Mr. Serafino’s legal fees, to be paid directly to counsel for Mr. Serafino within 30 days of receiving counsel’s invoice. Counsel for Mr. Serafino will
              provide an invoice and confirmation of such fees to Venus. Mr. Serafino hereby authorizes and directs such funds to be paid directly to Paliare Roland Rosenberg Rothstein LLP.

          

     

    	

          	9.	
            Venus will transfer $3,141.00 in travel credits to Mr. Serafino for personal use, broken down as follows, by no later than January 15, 2023;

          

    	

          	a.	
            0145889081024; YBCFMD; $2893; Air Canada; Expiry 21 Mar 23;

          

    	

          	b.	
            0165080128786; JDIXBB; $248; United Airlines; Expiry 31 Dec 22.

          

     

    	

          	10.	
            Mr. Serafino is required to keep the details of these Minutes of Settlement in strict confidence and not to disclose any details to anyone, except to the extent that such disclosure may or is
              required by law or to permit him to obtain tax planning, legal or similar advice and specifically in accordance with the Release and Indemnity.

          

    

    

    
      Page 2 of 5

      
        

    

    	

          	11.	
            Mr. Serafino agrees to comply with the restrictive covenants and other post-termination obligations set out in his Employment Agreement dated January 1, 2016 (the “Employment Agreement”) and at law, including, without limitation, resignation from director and/or officer positions (Section 4(i)); non-solicitation of clients, customers, employees, contractors
              (Section 4(f)); non-competition (Section 4(f)); and non-disclosure, confidentiality and return of Company property.

          

     

    	

          	12.	
            Mr. Serafino is required to sign and return the Release and Indemnity in the form attached at Schedule “A”.

          

    

    

    	

          	13.	
            The payments and benefits set out in these Minutes of Settlement are inclusive of any amounts which may be owing to Mr. Serafino arising from his employment with Venus, and the termination thereof,
              including but not limited to the following: payment(s) or remuneration of any kind; all payments pursuant to the ESA for termination pay, severance pay and vacation pay; any payments under any bonus plan; all payments under the Employment
              Agreement; and all payments under any applicable contract of insurance except as specifically set out herein.

          

    

    

    	

          	14.	
            The Parties agree that they will not disparage or criticize each other in any way, which includes specifically any internet or social media postings or comments, whether attributed or anonymous. With
              respect to Venus, this obligation applies to members of senior management only. Venus agrees to brief members of the senior management team during a regular meeting and in writing with respect to this obligation.

          

    

    

    	

          	15.	
            In the event of a breach of Mr. Serafino’s obligations set out in the Minutes of Settlement, which specifically include the obligations of confidentiality and non-disparagement, the payments and
              benefits herein will cease Venus shall have the right to pursue re-payment of monies paid, save and except amounts paid in respect of ESA entitlements.

          

    

    

    	

          	16.	
            Mr. Serafino confirms that he has had an opportunity and has, in fact, retained legal counsel with respect to the Minutes of Settlement and accepts the terms having considered and understood them,
              without duress.

          

     

    	

          	17.	
            The Parties agree the Minutes of Settlement may be executed electronically and in counter-part.

          

     

    IN WITNESS WHEREOF, the
        Parties have duly executed this Minutes of Settlement on December 30, 2022.

    

    

    	
            /s/ Scott Barry

          	 	 
	
            Venus Concept Canada Corp.

          	 
	
            By its authorized signing agent

          	
            

          

    	
            /s/ Domenic Serafino

          	 	
            /s/ Joanne Serafino

          	 
	
            Domenic Serafino

          	 	
            Witness

          

    

    

    
      Page 3 of 5

      
        

    

    SCHEDULE “A”

     

    RELEASE AND INDEMNITY

     

    IN CONSIDERATION of the terms and conditions of the
        Minutes of Settlement dated December 30, 2022 with Venus Concept Canada Corp. (“Venus”), and other
        good and valuable consideration, the receipt and sufficient of which is hereby acknowledged, I, Domenic Serafino, on behalf of myself, my heirs, successors, administrators
        and assigns (hereinafter collectively referred to as the “Releasor”) hereby release and forever discharge Venus,
        along with all parents, subsidiaries, affiliates and associated entities, and together with all respective officers, directors, employees, servants and agents and their successors and assigns (hereinafter collectively referred to as the “Releasee”) jointly and severally from any and all actions, causes of actions, contracts, covenants, whether express or implied, including but not limited to, any bonus claims of
        any nature and kind whatsoever, any vacation pay entitlements, any claims and demands for damages, including any disability claims, loss of benefit claims, claims for indemnity, costs, interest, and/or claims for loss or injury of every nature and
        kind whatsoever and howsoever arising, whether statutory or otherwise and specifically including, but not limited to the following: any claim under the Ontario Employment Standards
          Act, 2000 (including but not limited to claims for wages, notice, severance, vacation pay or termination pay); any claim under any applicable contract of insurance; any claim under the Ontario Human Rights Code, Labour Relations Act, Occupational Health and Safety Act and Workplace Safety and Insurance Act, and any successor
        legislation, which I may heretofore have had, may now have, or may hereinafter have, in any way relating to my hiring by, my employment by, or the cessation of my employment by the Releasee. For clarity, this Release does not apply to any claims to
        coverage that the Releasor may hold under (i) any director & officer liability insurance coverage held by Venus as of October 2, 2022, and (ii) any other indemnity provided to directors and officers of Venus as at October 2, 2022.

    

    

    AND FOR THE SAID CONSIDERATION, I hereby confirm
        that I have considered whether I may have, and confirm that I do not have any existing, planned or possible claim against the Releasee pursuant to the Ontario Human Rights Code,
        including specifically any claim of harassment, intimidation and other improper conduct, whether under the Ontario Human Rights Code or in tort, and I seek no right or
        remedy in respect of any such possible claim(s).

    

    

    AND FOR THE SAID CONSIDERATION, I further
        acknowledge, covenant and warrant that I have not filed with any Court, Commission or Agency, etc., including but not limited to the Employment Standards Branch of the
        Ministry of Labour, the Ontario Labour Relations Board, the Human Rights Tribunal of Ontario and the Pay Equity Commission of Ontario, any claim or complaint of the type described above, and that if such a claim or complaint has been filed, this
        Release and Indemnity, entered into freely and without duress, constitutes a full and final bar and/or answer to such claims or complaint. For clarity, I further agree that, as a condition of the Settlement, I will take all necessary steps to
        ensure the withdrawal or dismissal of such claim or complaint.

    

    

    AND FOR THE SAID CONSIDERATION, I further
        acknowledge, covenant and agree that in the event that I should hereafter make any claim, or demand or take any action or proceeding against the Releasee in connection with any matter covered by this Release and Indemnity, or threaten to do so,
        this document may be raised as an estoppel and complete bar to any such claim, demand, action or proceeding, and that I will be liable to the Releasee for its costs and expenses, including reasonable legal fees, incurred in responding thereto.

    

    

    AND FOR THE SAID CONSIDERATION, I further
        acknowledge, covenant and agree that I shall not make any claim or demand or take any action or proceeding in connection with any matter covered by this Release against any other employee, officer, person or corporation who might claim contribution
        or indemnity from the Releasee by virtue of the said claim or proceeding. I agree that if any such claim, demand, action or proceeding is made by me, the Releasee may raise this document as an estoppel and complete bar to any such claim,
      demand, action or proceeding and that I will be liable to the Releasee for its costs and expenses, including reasonable legal fees, incurred in responding thereto.

     

      

    
      Page 4 of 5

      
        

    

    AND FOR THE SAID CONSIDERATION, I further
        acknowledge, covenant and agree to save harmless and indemnity the Releasee from and against all claims, charges, taxes, penalties or demands which may be made by the Canada Revenue Agency requiring the Releasee to pay income tax, charges, taxes,
        or penalties under the Income Tax Act (Canada), in respect of amounts paid to me, in excess of income tax previously withheld; and in respect of any and all claims, charges,
        taxes or penalties and demands which may be made on behalf of or related to the Employment Insurance Commission and the Canada Pension Commission under the applicable statutes and regulations with respect to any amounts which may in the future be
        found to be payable to the Releasee in respect of the Releasor.

    

    

    AND FOR THE SAID CONSIDERATION, I further
        acknowledge, covenant and agree that during my employment I acquired confidential information which is the exclusive property of the Releasee which I shall not use in any manner without the express written permission of the Releasee. I recognize
        that all material and information that has been disclosed to me during my employment is confidential information that could be used to the detriment of the Releasee. As such, I will fulfill my obligations to hold confidential the information I
        received during my employment with the Releasee. I acknowledge and agree that the requirement to keep confidential the information acquired by me during my employment is reasonable and necessary for the protection of the Releasee.

    

    

    AND FOR THE SAID CONSIDERATION, I further
        acknowledge, covenant and agree that, notwithstanding the cessation of my employment, I will not discuss or disclose, to other than my immediate family members, legal advisors, financial advisors or as required by law, the terms of my settlement
        with the Releasee or this Release and Indemnity. Such disclosure shall include but is not limited to the posting of any comments or information concerning the terms and conditions of the settlement or this Release and Indemnity on the Internet or
        providing information for the posting of any comments related to this settlement.

    

    

    I HEREBY AGREE AND ACKNOWLEDGE THAT the
        consideration provided by the Releasee herein is not deemed to be an admission of liability on the part of the Releasee.

    

    

    I HEREBY AGREE AND ACKNOWLEDGE THAT in the event
        that any provision of this Release and Indemnity is deemed void, invalid or unenforceable by a court of competent jurisdiction, the remaining provisions shall remain in full force and effect.

    

    

    I HEREBY ACKNOWLEDGE AND CONFIRM that I have been
        afforded sufficient opportunity to obtain independent legal advice with respect to the details of the Settlement before accepting it and signing this Release and Indemnity. I further confirm that I have read this Release and Indemnity, understand
        it, and am executing it voluntarily and without duress after having been afforded the opportunity to obtain legal advice and having either received such advice or chosen not to do so.

     

      

    IN WITNESS WHEREOF, the Releasor had duly executed this Release and Indemnity this 29th day of December, 2022, in the
        presence of the witness whose signature is subscribed below.

    

    

    	
            /s/ Joanne Serafino

          	 	
            /s/ Domenic Serafino

          	 
	 	 	
            Domenic Serafino

          
	
            Witness Name:

          	
            Joanne Serafino

          	 	 

    

    

    

    

    Page 5 of 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]